Merrimack Pharmaceuticals Stock Debt To Equity
| MACK Stock | USD 14.74 0.01 0.07% |
Merrimack Pharmaceuticals fundamentals help investors to digest information that contributes to Merrimack Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Merrimack Stock. The fundamental analysis module provides a way to measure Merrimack Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Merrimack Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Debt To Equity | 0.23 | 0.24 |
Merrimack | Debt To Equity |
Merrimack Pharmaceuticals Company Debt To Equity Analysis
Merrimack Pharmaceuticals' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Merrimack Pharmaceuticals Debt To Equity | 33.90 % |
Most of Merrimack Pharmaceuticals' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Merrimack Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Merrimack Debt To Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Merrimack Pharmaceuticals is extremely important. It helps to project a fair market value of Merrimack Stock properly, considering its historical fundamentals such as Debt To Equity. Since Merrimack Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Merrimack Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Merrimack Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
Merrimack Total Stockholder Equity
Total Stockholder Equity |
|
According to the company disclosure, Merrimack Pharmaceuticals has a Debt To Equity of 33.9%. This is 36.68% lower than that of the Biotechnology sector and 75.1% higher than that of the Health Care industry. The debt to equity for all United States stocks is 30.39% higher than that of the company.
Merrimack Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Merrimack Pharmaceuticals' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Merrimack Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Merrimack Pharmaceuticals by comparing valuation metrics of similar companies.Merrimack Pharmaceuticals is currently under evaluation in debt to equity category among related companies.
Merrimack Fundamentals
| Return On Equity | -0.0622 | ||||
| Return On Asset | -0.0697 | ||||
| Current Valuation | 195.09 M | ||||
| Shares Outstanding | 14.53 M | ||||
| Shares Owned By Insiders | 1.21 % | ||||
| Shares Owned By Institutions | 66.10 % | ||||
| Number Of Shares Shorted | 815.87 K | ||||
| Price To Earning | 65.70 X | ||||
| Price To Book | 11.38 X | ||||
| Gross Profit | (9.1 M) | ||||
| EBITDA | (2.18 M) | ||||
| Net Income | (1.18 M) | ||||
| Cash And Equivalents | 13.36 M | ||||
| Cash Per Share | 1.00 X | ||||
| Debt To Equity | 33.90 % | ||||
| Current Ratio | 31.85 X | ||||
| Book Value Per Share | 1.31 X | ||||
| Cash Flow From Operations | (1.52 M) | ||||
| Short Ratio | 6.51 X | ||||
| Earnings Per Share | (0.08) X | ||||
| Price To Earnings To Growth | 0.07 X | ||||
| Target Price | 4.0 | ||||
| Beta | 1.43 | ||||
| Market Capitalization | 214.2 M | ||||
| Total Asset | 19.19 M | ||||
| Retained Earnings | (548.82 M) | ||||
| Working Capital | 18.74 M | ||||
| Current Asset | 89.62 M | ||||
| Current Liabilities | 88.28 M | ||||
| Net Asset | 19.19 M |
About Merrimack Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Merrimack Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Merrimack Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Merrimack Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Merrimack Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Merrimack Pharmaceuticals' short interest history, or implied volatility extrapolated from Merrimack Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Merrimack Pharmaceuticals Piotroski F Score and Merrimack Pharmaceuticals Altman Z Score analysis. For more information on how to buy Merrimack Stock please use our How to buy in Merrimack Stock guide.Note that the Merrimack Pharmaceuticals information on this page should be used as a complementary analysis to other Merrimack Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Merrimack Stock analysis
When running Merrimack Pharmaceuticals' price analysis, check to measure Merrimack Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merrimack Pharmaceuticals is operating at the current time. Most of Merrimack Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Merrimack Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merrimack Pharmaceuticals' price. Additionally, you may evaluate how the addition of Merrimack Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. |
Is Merrimack Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merrimack Pharmaceuticals. If investors know Merrimack will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merrimack Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.08) | Return On Assets (0.07) | Return On Equity (0.06) |
The market value of Merrimack Pharmaceuticals is measured differently than its book value, which is the value of Merrimack that is recorded on the company's balance sheet. Investors also form their own opinion of Merrimack Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Merrimack Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merrimack Pharmaceuticals' market value can be influenced by many factors that don't directly affect Merrimack Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merrimack Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Merrimack Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merrimack Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.